1
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
Condition(s):Hormone-Refractory Prostate CancerLast Updated:February 20, 2009Completed
Hide Studies Not Open or Pending
Condition(s):Hormone-Refractory Prostate CancerLast Updated:February 20, 2009Completed
Condition(s):HealthyLast Updated:June 9, 2011Completed
Condition(s):ContraceptionLast Updated:December 3, 2010Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.